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A B S T R A C T
Up to date, there is no information on the influence of 2,2,2-tribromoethanol (TBE; Avertin), a commonly used
anaesthetic, on mice with impaired antioxidant capacity. We aimed to analyse the effect of a single dose of
Avertin on anaesthesia duration time, inflammatory response, oxidative stress and collagen deposition in the
large intestine of Nrf2 transcriptional knockout mice (tNrf2−/−). The studies were performed on six-month-old
female mice Nrf2+/+ and tNrf2−/− randomly assigned to Avertin (250 mg/kg b.w. single i.p. injection) or
vehicle group. We observed a 2-fold increase in anaesthesia time and longer recovery time (p = 0.015) in
tNrf2−/− in comparison to Nrf2+/+. However, no hepato- or nephrotoxicity was detected. Interestingly, we
found severe changes in colon morphology of untreated tNrf2-/- mice associated with colon shortening (p =
0.02) and thickening (p = 0.015). Avertin treatment caused colon damage manifested with epithelial layer
damage and goblet depletion in Nrf2+/+ mice but not in tNrf2−/− individuals. Additionally, Avertin did not
induce oxidative stress in colon tissue, but it increased leukocyte infiltration in Nrf2+/+ mice (p = 0.02).
Immunofluorescent staining also revealed enhanced deposition of collagen I and collagen III in the colon of
untreated tNrf2−/− mice. Avertin contributed to increased deposition of collagen I in Nrf2+/+ mice but reduced
deposition of collagen I and III in tNrf2−/− individuals. In conclusion, tNrf2−/− respond to Avertin with pro-
longed anaesthesia that is not associated with acute toxicity, inflammatory reaction or enhanced oxidative stress.
Avertin does not impair intestine morphology in tNrf2−/− mice but can normalise the enhanced fibrosis.
1. Introduction
2,2,2-tribromoethanol (TBE; Avertin) has been used since 1926 as
an anaesthetic for dogs, cats, mice and rats [1,2]. It was usually injected
intraperitoneally in a single dose of 240−250 mg/kg and provided
short-term anaesthesia [3]. After administration, Avertin is metabolised
in the liver and excreted with the urine probably in a similar way to
other alcoholic xenobiotics [4]. However, its metabolism has not yet
been described in detail.
Although its use is considered safe in most common mouse strains
[5], studies are indicating its irritant and proinflammatory properties.
For instance, Thompson et al. [6] presented that even a single dose of
Avertin may cause damage of Kupffer and endothelial cells in the liver
and may increase the level of aminotransferases at 3 and 6 h after in-
jection. Moreover, Avertin may irritate the intestine leading to fibrosis
[7]. Nevertheless, it has been commonly used as a general anaesthetic,
since it is easy to prepare and rapidly induces anaesthesia with fast
recovery [8], along with low mortality and morbidity rate (< 1%) [9].
As Avertin is an alcoholic xenobiotic, it is of particular importance to
verify its effectiveness and safety in individuals with impaired detox-
ification and antioxidative reaction, such as Nrf2 (nuclear factor-ery-
throid 2 related factor 2)-defective mice.
Nrf2 is a transcription factor, which plays an essential role in the
regulation of detoxification, antioxidative, and anti-inflammatory re-
sponses [10,11] by binding to the antioxidant response elements (ARE)
in the promoters of target genes [12]. The Nrf2 transcriptional
knockout (tNrf2−/−) mice are viable and fertile but show increased
sensitivity to different xenobiotics including benzo(a)pyrene, butylated
hydroxytoluene, acetaminophen, and dextran sulphate sodium [re-
viewed in [13,14]]. Interestingly, although Nrf2 induces expression of
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antioxidative genes, the vascular system of tNrf2−/− mice does not
show any massive oxidative damage in steady-state conditions, despite
increased production of reactive oxygen species. Instead, the lack of
Nrf2 transcriptional activity drives the onset of premature senescence
[15] and protein aggregation [16] through non-canonical, Keap1 de-
pendent mechanisms [17]. Moreover, inhibition of Nrf2-regulated
genes may have a protective role against colon diseases [18–20]. It was
also shown that Nrf2 plays an essential role in colon fibrosis observed in
patients with ulcerative colitis and Crohn’s disease where inflamma-
tion, thickening of muscularis mucosae and collagen accumulation are
observed what may cause colon shortening [21].
To date, there is no information on how Avertin acts in mice with
impaired Nrf2 signalling. Therefore, the aim of this study was to ana-
lyse the influence of a single dose of Avertin on anaesthesia duration
time, inflammatory response, oxidative stress and collagen deposition
in the large intestine of Nrf2 transcriptional knockout mice.
2. Material and methods
2.1. Animals and housing
Experiments were performed on C57/BL6 mice with the normal
level of Nrf2 (Nrf2+/+), and on B6.129 × 1-Nfe2l2tm1Ywk mice lacking
transcriptionally active Nrf2 (tNrf2−/−). Mice were generated by Prof.
Masayuki Yamamoto [12] and kindly provided by Prof. Antonio Cua-
drado (Universidad Autonoma de Madrid, Spain). In tNrf2+/+ mice,
the DNA binding domain of Nrf2 was replaced by LacZ gene, to gen-
erate a fusion protein N-terminal Nrf2-β-galactosidase [22,23].
The animals were maintained in the SPF (specific pathogen-free)
animal facility at the Faculty of Biochemistry, Biophysics and
Biotechnology, under a constant 12 h dark/light cycle at the environ-
mental temperature of 22± 2 °C and were provided with standard la-
boratory pellet diet and water ad libitum. For experiments, 6-month-old
female mice with verified genotype by PCR method were used.
The study was carried out in accordance with the European
Communities Council Directive (2010/663/UE) and with the national
recommendations. The experimental protocol was approved by the
Second Local Ethics Committee for Animal Research in Krakow (No.
77/2018).
2.2. Avertin efficacy and toxicity
Nrf2+/+ and tNrf2−/− female mice were randomly assigned to one
of two groups to receive a single i.p. injection of Avertin (250 mg/kg
b.w.; 1.2 % solution, 0.5 mL) or vehicle (0.5 mL), mentioned as control.
Avertin treated mice contained 6 animals and control mice contained 5
animals. Avertin was prepared as recommended at the Baylor College of
Medicine [24]. Briefly, a 1.6-g/mL stock solution was prepared by
adding 0.5 mL tert-amyl alcohol (Sigma–Aldrich) to 0.25 g 2,2,2-tri-
bromoethanol (99 %; Sigma-Aldrich). A 20-mg/mL working solution
was prepared by adding 0.5 mL of the tribromoethanol stock solution to
39.5 mL sterile saline (Polpharma); the working solution was filtered
through a 0.2-mm syringe filter (Fisher Scientific). The stock solution
was made 1 day before injection and allowed to stir overnight at room
temperature; the working solution was made immediately prior to in-
jection. Vehicle was prepared as above without the addition of 2,2,2-
tribromoethanol.
After Avertin injection mice were placed on a digital thermo-
regulated heating pad (37 °C, Techniplast) with eye lubricant for pro-
tection, and the duration of anaesthesia, and recovery time were
monitored. The anaesthetic duration was defined as the time between
the loss and return of the pedal reflex [minutes]. Presence of the pedal
reflex was defined as the withdrawal of the limb after pinching with
tweezers. Recovery time [minutes] was defined as mouse ability to
maintain an upright posture and walking normally around the cage.
Next, 3 h and 6 h after injection the venous blood was collected to
serum separator tubes to assess the levels of glucose and selected
markers of liver damage (alkaline phosphatase (ALP) and alanine
aminotransferase (ALT)) and kidney damage (creatinine, urea nitrogen,
and total protein). Biochemical analysis was made in 100 μL of serum
using SpotChem EZ Analyzer and ready-to-use stripes (Panel V;
Woodley equipment).
2.3. Colon harvesting
Twenty-eight days after treatment mice were sacrificed by exposure
to carbon dioxide inhalation, followed by cervical dislocation. Next,
large intestine was dissected and subjected to macroscopic scoring of
colon length and wall thickness, followed by tissue preservation for
myeloperoxidase (MPO) activity assay, malondialdehyde (MDA) assay,
histological staining, and gene expression analysis.
2.4. Histological stainings
After macroscopic evaluation, segments of the distal colon were
stapled flat, mucosal side up, onto cardboard and fixed in 10 % neutral-
buffered formalin for 24 h at 4 °C. Samples were then dehydrated,
embedded in paraffin, sectioned at 5 μm (microtome Thermo Fisher
Scientific), and mounted onto slides. Next, specimens were depar-
affinised and stained using haematoxylin and eosin (H&E; for general
morphology) or Trichrome staining (for collagen detection) using tissue
strainer (Thermo Fisher Scientific) and commercially available reagents
and kits (Sigma-Aldrich). Samples were analysed under a light micro-
scope (Nikon, Eclipse Ti-S). Each time 3 separate tissue scraps from the
same sample were analysed.
2.5. Microscopic scoring
Microscopic scoring was performed as previously described [25].
Sections stained with H&E were examined using a Nikon Eclipse Ti-S
microscope. Photographs were taken and analysed using Image J soft-
ware (Wayne-Rasband (NIH)). Microscopic total damage score was
determined in blind manner based on the presence (score = 1) or ab-
sence (score = 0) of goblet cell depletion, the presence (score = 1) or
absence (score = 0) of crypt abscesses, the destruction of mucosal ar-
chitecture (normal = 1, moderate = 2, extensive = 3), the extent of
muscle thickening (normal = 1, moderate = 2, extensive = 3), and the
presence and degree of cellular infiltration (normal = 1, moderate = 2,
transmural = 3).
Change in collagen content (Trichrome staining) was assessed ba-
sing on the intensity of collagen (blue colour) staining in the intestinal
crypts, muscularis mucosa and submucosa using the following scale:
1=small, 2=medium, 3=excessive collagen intensity staining. The
total sum of points indicated the final collagen content in the sample.
Each time 3 tissue scraps and 4 fields were counted. The analysis was
blinded and performed independently by three researchers.
2.6. Immunofluorescence
Paraffinized samples were cut to 5 μm slices using a microtome
(Thermo Fisher Scientific), deparaffinised and boiled for 15 min in a
citric acid buffer (pH 6.0) to activate antigen, permeabilised in 0.01 %
Triton X-100 for 2 min, washed and incubated with 0.25 % glycine in
PBS for 30 min. Next, tissue scraps were blocked for 1 h in 3% goat
serum (GS) at room temperature. After washing in PBS, samples were
incubated overnight (4 °C) with rat anti-mouse CD45 polyclonal anti-
bodies (dilution 1:50, Invitrogen) or rabbit anti-mouse collagen type I
or type III antibodies (1:250, Abcam) diluted in 1% GS. At the next day,
samples were washed and incubated with anti-rat or anti-rabbit anti-
body conjugated with Alexa Fluor 488 (dilution 1:1000; IgG H+ L, Life
Technologies) for 1 h at room temperature. Nuclei were counterstained
with Hoechst 33342 (dilution 1:10,000). Samples were analysed under
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a fluorescent microscope (Nikon, Eclipse Ti-S).
2.7. MPO assay
The myeloperoxidase (MPO) activity assay, which is an indicator of
granulocyte infiltration [26], was performed as previously described by
Salaga et al. [27]. Briefly, 1 cm segments of colon were weighed and
homogenized in hexadecyltrimethylammonium bromide buffer (0.5 %
in 50 mM potassium phosphate buffer, pH 6.0; 1:20 w/v). Next, the
homogenate was centrifuged (15 min, 13,200 g, 4 °C) and 200 μl of 50
mM potassium phosphate buffer (pH 6.0), containing 0.167 mg/mL of
O-dianisidine hydrochloride and 0.05 μl of 1% hydrogen peroxide was
added to 7 μl of supernatant. Absorbance was measured at 450 nm
(iMARK Microplate Reader; Biorad). MPO was expressed in milliunits
per gram of wet tissue, 1 unit being the quantity of enzyme able to
convert 1 μmol of hydrogen peroxide to water in 1 min at room tem-
perature. Units of MPO activity per 1 min were calculated from a
standard curve using purified peroxidase enzyme.
2.8. MDA assay
5 mg of large intestine tissue was homogenised in 200 μL of lysis
buffer (w/v) containing 20 % (w/v) trichloroacetic acid and 0.8 % (w/
v) thiobarbituric acid (Sigma-Aldrich). Next, samples were boiled for 30
min and centrifuged (300g, 10 min). The absorbance of the supernatant
was measured at 535 nm with the correction wavelength of 600 nm for
the nonspecific turbidity (Infinite 200 Pro, Tecan). The amount of MDA
was calculated using the extinction coefficient of MDA-TBA complex,
which is 1.56 × 105 M−1 cm−1, and the results were expressed as mM
MDA/mg tissue.
2.9. Analysis of gene expression
RNA from 30 mg of large intestine tissue was extracted with RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions. cDNA
was synthesised using High-Capacity cDNA Reverse Transcription Kit
(Thermo Fisher Scientific). RT-qPCR was conducted on Step-One Plus
Real-Time PCR Systems using a Power SYBR® Green PCR Master Mix
according to the manufacturer’s instructions (Thermo Fisher Scientific).
Primer sequences and their efficiency are gathered in Table 1. Eu-
karyotic mouse translation elongation factor 2 (Eef-2) was used as a
reference gene. The results were calculated using the relative expres-
sion method.
2.10. Statistical analysis
Data are presented as mean± S.E.M. with individual values.
Depending on the normality of distribution, the comparisons between
groups were performed using the Student’s t-test or Mann-Whitney test
for two-group comparisons. Multiple comparisons were made using
two-way or three-way analysis of variance (ANOVA), followed by the
Dunn’s post-hoc test (GraphPad Prism software).
3. Results
3.1. Avertin causes prolonged anaesthesia and delayed recovery in mice
with transcriptionally inactive Nrf2
Mice with transcriptionally inactive Nrf2 (tNrf2−/−) responded
differently to Avertin-induced anaesthesia than their wild type (Nrf2+/
+) counterparts. We observed a 2-fold increase in anaesthesia time in
tNrf2−/− in comparison to Nrf2+/+ counterparts (21± 3 min vs 9±1
min; p = 0.02; Fig. 1A). Moreover, tNrf2−/− mice had prolonged re-
covery time (72± 5 vs 53±5 min; p = 0.015; Fig. 1B). These results
might suggest that animals with impaired transcriptional activity of
Nrf2 may metabolise Avertin more slowly than mice with the normal
transcriptional activity of Nrf2.
3.2. A single dose of Avertin provokes no hepato- and nephrotoxicity in
tNrf2−/− mice
To verify the toxicity of a single dose of Avertin, we analysed
changes in selected biochemical parameters, associated with liver and
kidney function - main metabolising organs of Avertin - in the blood at
3 h and 6 h post-treatment (Fig. 2). We found that a single dose of
Avertin in wild type mice caused a significant increase in ALT at both
time points (p = 0.04 for 3 h and p = 0.02 for 6 h; Fig. 2A), however, a
decrease in ALP after 3 h (p = 0.04, Fig. 2B) compared to the untreated
control. Of note, the level of ALT was at the lower range of grade 1
hepatotoxicity score, which is 51–125 IU/L [28]. No significant changes
in ALT and ALP were observed in tNrf2−/− mice treated with Avertin
(Fig. 2A,B). On the other hand, in tNrf2 mice serum there was a de-
crease in creatinine (p = 0.03; Fig. 2C), total protein level (p = 0.02)
but not urea nitrogen (Fig. 2D) after 3 h compared to the control. A
similar trend, although less pronounced, was also observed in the
Nrf2+/+. No significant changes in plasma glucose were detected in
both genotypes (Fig. 2E,F). Therefore, a single dose of Avertin provokes
some changes in liver-damage markers in NRf2+/+ mice and kidney-
damage markers in Nrf2−/− animals. However, Avertin is not hepato-
toxic and does not change ASP and ALT levels in tNrf2−/− mice, de-
spite a significant influence on anaesthesia duration time.
3.3. A single dose of Avertin impairs colon morphology in Nrf2+/+ but not
in tNrf2−/− mice
Different response to anaesthetic treatment may result from altered
colon absorption. Thus we inspected it further. We observed significant
changes in colon morphology. Macroscopic analysis showed that the
colon was shorter (p = 0.02, Fig. 3A) and tended to be thicker (p =
0.15, Fig. 3B) in the untreated tNrf2−/− than in Nrf2+/+ mice. Which
was also visible at microscopic level on histological slides as thickening
of the muscular layer (marked with asterisk on Fig. 3C). Those changes
Table 1
The sequence of primers used in the study.
Gene Primer sequence 5′-3′ Primer efficiency [%]
Mouse Col1α1 F: 5′- ACTACCGGGCCGATGATGCTAACG -3′ R: 5′- CGATCCAGTACTCTCCGCTCTTCC -3′ 113.7
Mouse Col1α2 F: 5′- GCCACCATTGATAGTCTCTCC -3′ R: 5′- CACCCCAGCGAAGAACTCATA -3′ 115.8
Mouse Col3α1 F: 5′- ATCTATGAATGGTGGTTTTCAGTT -3′ R: 5′- TTTTGCAGTGGTATGTAATGTTCT -3′ 108.2
Mouse Col4α1 F: 5′- CAGATTCCGCAGTGCCCTA -3′R: 5′- GGAATAGCCGATCCACAGTGAG -3′ 104.4
Mouse TNF-α F: 5′- GACCCTCACACTCAGATCATCTTCT-3′ R: 5′- CCACTTGGTGGTTTGCTACGA -3′ 118.2
Mouse IL-4 F: 5′- CTGGTGTGTGACGTTCCCATTA -3′ R: 5′- CCGACAGCACGAGGCTTT -3′ 97.6
Mouse IL-1β F: 5′- CTGGTGTGTGACGTTCCCATTA-3′ R: 5′- CCGACAGCACGAGGCTTT -3′ 114.5
Mouse IL-6 F: 5′-AAAGAGTTGTGCAATGCAATGGCAATTCT-3′ R: 5′- AAGTGCATCATCGTTGTTCATACA -3′ 98.2
Mouse MCP-1 F: 5′- GGCTCAGCCAGATGCAGTTAA -3′ R: 5′- CCTACTCATTGGGACTCATCTTCT -3′ 107.2
Mouse Ef-2 F: 5′- GACATCACCAAGGGTGTGCA -3′ R: 5′- TCAGCACACTGGCATAGACC -3′ 92.4
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were not influenced by different body weight in both genotypes
(24.98±0.34 g for Nrf2+/+ vs 23.26± 0.76 g for tNrf2−/−; p =
0.11). Thus, lack of transcriptionally active Nrf2 worsens colon mor-
phology in adult female mice.
Of note, as the experiments were performed on 6 month-old mice,
some age-related changes in the colon structure were noticed in control
Nrf2+/+ animals and were reflected in higher microscopic scoring than
expected (Fig. 3D).
Looking further, and given the fact that Avertin may lead to in-
testinal fibrosis [7], we checked the long term effect of a single dose of
Avertin on the colon morphology. Four weeks after administration,
Avertin did not significantly influence the colon length or colon
thickness in the wild type mice, but it tended to attenuate the difference
between the length of colons in tNrf2−/− individuals (p = 0.057;
Fig. 3A). However, histological analysis indicated that Avertin impaired
colon morphology in Nrf2+/+ mice manifested as epithelial layer da-
mage and goblet depletion (marked with arrows on Fig. 3C). All those
differences were reflected in the higher macroscopic score in Avertin
treated Nrf2+/+ mice compared to the control (p = 0.015; Fig. 3D). On
the contrary, Avertin-treated tNrf2-/- mice underwent positive changes
in colon morphology represented as a thinner muscular layer (Fig. 3C
and Suppl. 1) and lower microscopic score compared to Avertin-treated
Nrf2+/+ (p = 0.03; Fig. 3D). Thus, Avertin contributes to colon da-
mage in Nrf2+/+ mice but improves the disturbed colon morphology in
tNrf2−/− individuals.
3.4. Colon morphological changes in tNrf2−/− mice treated with Avertin
are accompanied by altered expression of collagens but not with oxidative
stress or inflammation
To shed some light on possible causes of changes in colon mor-
phology in the untreated and Avertin-treated tNrf2−/− mice, we
evaluated oxidative stress, inflammation and expression of collagens in
the colon wall. The results showed that the untreated tNrf2−/− mice
have a similar level of MPO activity and lipid peroxidation in the colon
compared to the untreated wildtype control and that Avertin did not
influence these parameters in any of the genotypes. Therefore, we
suspect that excessive oxidative stress is not the reason for colon da-
mage in tNrf2−/− mice and Nrf2+/+ mice treated with Avertin (Fig. 4).
Further, there was no difference between the untreated animals of
both genotypes in the inflammatory response, as leukocyte infiltration
(CD45+ cells) and levels of proinflammatory cytokines (TNFα, IL-6, IL-
1β, MCP-1) were similar (Fig. 5A-C). Treatment with Avertin increased
leukocyte infiltration (p = 0.02; Fig. 5A,B) and TNFα mRNA level (p =
0.009; Fig. 5C) in the wild type mice. Surprisingly, the tNrf2−/− mice
were resistant to Avertin-mediated proinflammatory changes.
Given the fact that abnormal collagen production and deposition is
conducive for many colon-related disorders and is directly associated
with inflammatory response, we analysed the expression of collagens
within the colon tissue. First, we inspected total collagen content by
Trichrome staining (Fig. 6A,B). It revealed that untreated tNrf2−/−
mice have higher collagen content comparing to their wildtype coun-
terparts (p = 0.04; Fig. 6A,B). Moreover, while Nrf2+/+ mice treated
with Avertin showed a tendency to increased expression of Col1a1
mRNA, a similar trend was not observed in tNrf2−/− mice. Instead,
Fig. 1. Avertin causes prolonged anaesthesia
and delayed recovery in mice with tran-
scriptionally inactive Nrf2. Duration of (A)
anaesthesia, and (B) recovery in 6-month-old
female Nrf2+/+ and tNrf2−/− mice divided
randomly into control (n = 5) and Avertin (n
= 6) groups. Mice were treated in-
traperitoneally with a single dose of Avertin
or vehicle. Values are expressed as
mean± S.E.M. Two-tailed Student’s t-test.
Fig. 2. A single dose of Avertin provokes no hepato- and nephrotoxicity in tNrf2−/− mice. Serum concentration of liver-damage markers (A) alanine amino-
transferase (ALT); (B) alkaline phosphatase (ALP); kidney-damage markers (C) creatinin (Cre); (D) total protein; (E) urea nitrogen, and (F) glucose in 6 month old
female Nrf2+/+ and tNrf2−/− mice treated intra peritoneally with a single dose of Avertin or vehicle. Mice were divided randomly into control (n = 5) and Avertin
(n = 6) groups. Data are presented as mean± S.E.M. Three-way ANOVA with Dunn’s post-hoc test.
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there was a decrease in the expression of Col3a1 (p = 0.02) and a
tendency for increased expression of Col4a1 transcript (Fig. 6C). Im-
munofluorescent staining revealed enhanced deposition of collagen I
and collagen III in the colon of untreated tNrf2−/− mice and mainly
collagen I in the Avertin treated Nrf2+/+ mice (Fig. 6D). Accordingly,
analysis of mRNA expression, the immunostaining showed that a single
dose of Avertin causes increased deposition of collagen I in Nrf2+/+
mice but reduces deposition of collagen I and III in tNrf2−/− in-
dividuals (Fig. 6D,E).
Fig. 3. A single dose of Avertin impairs colon morphology in Nrf2+/+ but not in tNrf2−/− mice. The change in (A) colon length to body weight (BW); (B)
macroscopic large intestine thickness; (C) representative images of microscopic changes in colon morphology (H&E staining at magnification 200x; arrow - goblet
cells depletion; asterisk - muscularis mucosae thickening); and (D) microscopic scoring (based on histological slides) of the colon in mice 28-days after a single dose of
Avertin (n = 6) or vehicle (n = 5). Data in panels A, B and D are presented as mean± S.E.M. Two-way ANOVA with Dunn’s post-hoc test.
Fig. 4. Avertin treatment has no influence on
colon oxidative stress. The changes in (A) MPO
activity and (B) lipid peroxidation (MDA) in
mice 28-days after a single dose of Avertin or
vehicle. Mice were divided randomly into
control (n = 5) and Avertin (n = 6) groups.
Data are presented as mean± S.E.M. Two-way
ANOVA with Dunn’s post-hoc test.
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4. Discussion
We show in this study that Avertin is non-toxic, yet it causes pro-
longed anaesthesia in mice with transcriptionally inactive Nrf2. We also
found that these mice have changed morphology and collagen dis-
tribution in the large intestine when compared to the wild type animals.
Treatment with Avertin did not further impair those changes but in-
stead tended to improve them. On the other hand, even a single dose of
Avertin may adversely affect the morphology of intestine in the wild
type animals. The above should be taken into account when planning
anaesthesia.
It is known that response to anaesthetic strongly depends on me-
tabolism rate and body antioxidant ability. A recent study showed that
exposure of rats to injected (propofol) or inhaled (isoflurane) anaes-
thetics induced enhanced glutathione (GSH) production, which results
from the Nrf2-dependent expression of the excitatory amino acid carrier
1 (EAAC1) in the hippocampus [29]. It is known that different anaes-
thetics may activate Nrf2 via phosphoinositide-3-kinase and protein
kinase B (PI3K/Akt), contributing to an enhancement of antioxidant
response [30,31]. Therefore, Nrf2 activation likely acts as a defence
mechanism against oxidative stress during anaesthesia. However,
tNrf2−/− animals did not show signs of significant oxidative stress even
after treatment with Avertin, which supports our earlier observations
[15,32]. Hence, prolonged anaesthetic time does not seem to be oxi-
dative stress-dependent, but rather might be related to impaired de-
toxification of xenobiotics [11,12].
Moreover, despite prolonged anaesthesia, no changes in ASP, ALT or
creatinine was observed in the blood of tNrf2−/− mice, revealing no
acute hepato- or nephrotoxicity of Avertin. This observation was sur-
prising, as activation of Nrf2 reduced or prevented the xenobiotics-in-
duced toxicity in many experimental settings [reviewed in [33]]. In-
terestingly, we found that the colon structure in tNrf2−/− mice
resembled the one observed during dextran sulphate sodium (DSS)-in-
duced colitis [34]. Thus, we suppose that the prolonged anaesthesia in
case of tNrf2−/− mice might be associated with impaired Avertin ab-
sorption within the intestine.
Fig. 5. Colon morphological changes in
tNrf2−/− mice are not associated with in-
flammatory response. (A) Representative
images of immunofluorescent staining of
CD45 cells within the colon (magnification
400 × . CD45 - green, nuclei - blue, arrows
indicate CD45+ cells) with (B) relative
number of CD45+ cells infiltrating colon
tissue; (C) relative expression of TNFα, IL-6,
IL-1β, MCP-1, and IL-4. Eef2 was used as a
reference gene. Mice were sacrificed 28-days
after a single administration of Avertin (n =
6) or vehicle (n = 5). Data in panels B and C
are presented as mean± S.E.M. Two-way
ANOVA with Dunn’s post-hoc test. (For in-
terpretation of the references to colour in the
Figure, the reader is referred to the web
version of this article).
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We also found that, differently than in the wild type animals, a
single dose of Avertin can improve colon morphology in the tNrf2−/−.
One could expect that such improvement should be related to decreased
inflammation or oxidative stress. Nrf2 is a key transcription factor
which influences the expression of antioxidant and anti-inflammatory
genes [35]. It was previously reported that Nrf2-deficient mice had
increased level of some proinflammatory cytokines, which could pre-
dispose them to DSS-induced colitis [36]. On the other hand, it was
shown that prolonged activation of Nrf2 triggers inflammation and
increases the risk of colon cancer [37]. However, in our experimental
settings, the colon lengthening in tNrf2−/− mice treated with Avertin
was independent of oxidative stress or inflammation. Of note, Nrf2
plays a role in the release of calcium ions and limits excessive stimu-
lation of the sympathetic system, which influence contractility of colon
tissue [38]. In accordance, Nrf2-deficient mice show a higher suscept-
ibility of the colon to acetylcholine [39].
Another cause of improvement of colon morphology in tNrf2−/−
mice after Avertin could be related to changes in the production of
extracellular matrix (ECM) proteins, mainly collagens. In our study, the
lack of transcriptionally active Nrf2 resulted in a significant deposition
of collagen, particularly type III, mostly within lamina propria.
Inflammatory colon diseases are associated with tissue fibrosis [40]. It
was previously shown that Nrf2-deficient mice have higher expression
of collagen type I, III and fibronectin in the skin [41]. Additionally,
impaired tissue regeneration was observed in those mice [42]. In ac-
cordance, Nrf2 activation protects against fibrosis in lungs [43],
whereas protracted activation of Nrf2 results in overexpression of P450
cytochromes, inflammation, fibrosis and eventually cancer formation
[44]. What is more, Nrf2 activation during xenobiotics metabolism was
also associated with retardation of structural cytoskeletal and ECM
proteins [45]. Therefore, Nrf2 activity can regulate the production of
ECM proteins within large intestine tissue. Our results suggest that a
single dose of Avertin administered to tNrf2−/− mice may reduce the
collagen accumulation in the intestine. On the other hand, in the wild
type animals, Avertin can induce colon fibrosis which may be asso-
ciated with higher deposition of collagens. Nevertheless, further studies
on the role of Nrf2 in xenobiotics absorption and metabolism should be
addressed. Deepen examination of the influence of transcriptional ac-
tivity of Nrf2 in the colon development as well as functionality, which
may depend not only on sex but also on age could shed a light on this
sparsely understood topic.
In conclusion, mice lacking transcriptionally active Nrf2 respond to
Avertin with prolonged anaesthesia that is not associated with acute
toxicity, inflammatory reaction or enhanced oxidative stress. Moreover,
Fig. 6. Colon morphological changes in
tNrf2−/− mice treated with Avertin are ac-
companied by altered expression of collagens.
(A) Representative images of total collagen
content (blue; magnification 200x) with (B)
microscopic scoring of total collagen; (C) re-
lative expression of Col1α1, Col1α2, Col3, and
Col4. Eef2 was used as a reference gene; and
(D) representative immunofluorescent
staining of collagen type I and III within the
colon (magnification 100x. Collagen - green,
nuclei – blue). Mice were sacrificed 28-days
after a single administration of Avertin (n =
6) or vehicle (n = 5). Data in panels B and C
are presented as mean±S.E.M. Two-way
ANOVA with Dunn’s post-hoc test. (For inter-
pretation of the references to colour in the
Figure, the reader is referred to the web ver-
sion of this article).
A. Kopacz, et al. Biomedicine & Pharmacotherapy 128 (2020) 110317
7
Avertin does not impair intestine morphology in Nrf2−/− mice but can
normalise the enhanced fibrosis.
Funding
The study was supported by the Fuga IV program of the National
Science Centre (DEC-2015/16/S/NZ4/00040 awarded to APP) and the
Sonata 14 program of the National Science Centre (2018/31/D/NZ4/
00077 awarded to APP). DK acknowledges financial support from the
National Science Centre under the ETIUDA doctoral scholarship on the
basis of the decision number DEC-2019/32/T/NZ3/00326. The Faculty
of Biochemistry, Biophysics and Biotechnology of the Jagiellonian
University is a partner of the Leading National Research Centre
(KNOW) supported by the Ministry of Science and Higher Education.
Authors contribution
Participated in research design: APP, AK. Conducted experiments:
APP, AK, EW, DK, KH. Performed data analysis: AK, APP. Wrote or
contributed to the writing of the manuscript: APP, AK, AJ, JF.
Declaration of Competing Interest
The author(s) declared no potential conflicts of interest concerning
the research, authorship, and/or publication of this article.
Acknowledgements
We would like to express great appreciation to Anna Grochot-
Przeczek, PhD for her valuable and constructive suggestions during the
research work and the manuscript preparation.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.biopha.2020.110317.
References
[1] P. Chieco, P. Hrelia, S. Candeletti, S. Ferri, G. Cantelli Forti, Methadone affects the
histochemical pattern of xenobiotic-metabolizing enzymes in the liver of pregnant
rats, Arch. Toxicol. Suppl. Arch. Toxikol. Suppl. 7 (1984) 261–265.
[2] M.L. Norris, W.D. Turner, An evaluation of tribromoethanol (TBE) as an anaesthetic
agent in the Mongolian gerbil (Meriones unguiculatus), Lab. Anim. 17 (1983)
324–329, https://doi.org/10.1258/002367783781062370.
[3] Laboratory Animal Anaesthesia - 3rd Edition, (n.d.). https://www.elsevier.com/
books/laboratory-animal-anaesthesia/flecknell/978-0-12-369376-1 (Accessed
September 4, 2018).
[4] R.E. Meyer, R.E. Fish, A review of tribromoethanol anesthesia for production of
genetically engineered mice and rats, Lab Anim. 34 (2005) 47–52, https://doi.org/
10.1038/laban1105-47.
[5] W.A. Hill, J.T. Tubbs, C.L. Carter, J.A. Czarra, K.M. Newkirk, T.E. Sparer,
B. Rohrbach, C.M. Egger, Repeated administration of tribromoethanol in C57BL/
6NHsd mice, J. Am, Assoc. Lab. Anim. Sci. JAALAS. 52 (2013) 176–179.
[6] J.S. Thompson, S.A. Brown, V. Khurdayan, A. Zeynalzadedan, P.G. Sullivan,
S.W. Scheff, Early effects of tribromoethanol, ketamine/xylazine, pentobarbitol,
and isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice, Comp. Med.
52 (2002) 63–67.
[7] W. Zeller, G. Meier, K. Bürki, B. Panoussis, Adverse effects of tribromoethanol as
used in the production of transgenic mice, Lab. Anim. 32 (1998) 407–413, https://
doi.org/10.1258/002367798780599811.
[8] W.A. Hill, J.T. Tubbs, C.L. Carter, J.A. Czarra, K.M. Newkirk, T.E. Sparer,
B. Rohrbach, C.M. Egger, Repeated administration of tribromoethanol in C57BL/
6NHsd mice, J. Am. Assoc. Lab. Anim. Sci. JAALAS. 52 (2013) 176–179.
[9] V.E. Papaioannou, J.G. Fox, Efficacy of tribromoethanol anesthesia in mice, Lab.
Anim. Sci. 43 (1993) 189–192.
[10] U. Florczyk, A. Jazwa, M. Maleszewska, M. Mendel, K. Szade, M. Kozakowska,
A. Grochot-Przeczek, M. Viscardi, S. Czauderna, K. Bukowska-Strakova,
J. Kotlinowski, A. Jozkowicz, A. Loboda, J. Dulak, Nrf2 regulates angiogenesis:
effect on endothelial cells, bone marrow-derived proangiogenic cells and hind limb
ischemia, Antioxid. Redox Signal. 20 (2014) 1693–1708, https://doi.org/10.1089/
ars.2013.5219.
[11] A. Loboda, M. Damulewicz, E. Pyza, A. Jozkowicz, J. Dulak, Role of Nrf2/HO-1
system in development, oxidative stress response and diseases: an evolutionarily
conserved mechanism, Cell. Mol. Life Sci. CMLS. 73 (2016) 3221–3247, https://doi.
org/10.1007/s00018-016-2223-0.
[12] K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi,
K. Satoh, I. Hatayama, M. Yamamoto, Y. Nabeshima, An Nrf2/Small maf hetero-
dimer mediates the induction of phase II detoxifying enzyme genes through anti-
oxidant response elements, Biochem. Biophys. Res. Commun. 236 (1997) 313–322,
https://doi.org/10.1006/bbrc.1997.6943.
[13] L. Baird, A.T. Dinkova-Kostova, The cytoprotective role of the Keap1-Nrf2 pathway,
Arch. Toxicol. 85 (2011) 241–272, https://doi.org/10.1007/s00204-011-0674-5.
[14] D. Kloska, A. Kopacz, A. Piechota-Polanczyk, W. Nowak, J. Dulak, A. Jozkowicz,
A. Grochot-Przeczek, Nrf2 in aging - Focus on the cardiovascular system, Vascul.
Pharmacol. (2018), https://doi.org/10.1016/j.vph.2018.08.009.
[15] A. Kopacz, D. Klóska, B. Proniewski, D. Cysewski, N. Personnic, A. Piechota-
Polańczyk, P. Kaczara, A. Zakrzewska, H.J. Forman, J. Dulak, A. Józkowicz,
A. Grochot-Przęczek, Keap1 controls protein S-nitrosation and apoptosis-senescence
switch in endothelial cells, Redox Biol. 28 (2020) 101304, , https://doi.org/10.
1016/j.redox.2019.101304.
[16] A. Kopacz, D. Kloska, M. Targosz-Korecka, B. Zapotoczny, D. Cysewski,
N. Personnic, E. Werner, K. Hajduk, A. Jozkowicz, A. Grochot-Przeczek, Keap1
governs ageing-induced protein aggregation in endothelial cells, Redox Biol. (2020)
101572, https://doi.org/10.1016/j.redox.2020.101572.
[17] A. Kopacz, D. Kloska, H.J. Forman, A. Jozkowicz, A. Grochot-Przeczek, Beyond
repression of Nrf2: an update on Keap1, Free Radic. Biol. Med. (2020), https://doi.
org/10.1016/j.freeradbiomed.2020.03.023.
[18] A. Piechota-Polanczyk, J. Fichna, Review article: the role of oxidative stress in
pathogenesis and treatment of inflammatory bowel diseases, Naunyn
Schmiedebergs Arch. Pharmacol. 387 (2014) 605–620, https://doi.org/10.1007/
s00210-014-0985-1.
[19] A. Piechota-Polanczyk, M. Zielińska, D. Piekielny, J. Fichna, The influence of lipoic
acid on caveolin-1-regulated antioxidative enzymes in the mouse model of acute
ulcerative colitis, Biomed. Pharmacother. Biomedecine Pharmacother. 84 (2016)
470–475, https://doi.org/10.1016/j.biopha.2016.09.066.
[20] A. Piechota-Polanczyk, M. Włodarczyk, A. Sobolewska-Włodarczyk, M. Jonakowski,
A. Pilarczyk, K. Stec-Michalska, M. Wiśniewska-Jarosińska, J. Fichna, Serum cy-
clophilin a correlates with increased tissue MMP-9 in patients with ulcerative co-
litis, but not with Crohn’s disease, Dig. Dis. Sci. 62 (2017) 1511–1517, https://doi.
org/10.1007/s10620-017-4568-0.
[21] J.P. Burke, J.J. Mulsow, C. O’Keane, N.G. Docherty, R.W.G. Watson, P.R. O’Connell,
Fibrogenesis in Crohn’s disease, Am. J. Gastroenterol. 102 (2007) 439–448, https://
doi.org/10.1111/j.1572-0241.2006.01010.x.
[22] K. Itoh, J. Mimura, M. Yamamoto, Discovery of the negative regulator of Nrf2,
Keap1: a historical overview, Antioxid. Redox Signal. 13 (2010) 1665–1678,
https://doi.org/10.1089/ars.2010.3222.
[23] K. Itoh, N. Wakabayashi, Y. Katoh, T. Ishii, T. O’Connor, M. Yamamoto, Keap1
regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to
electrophiles, Genes Cells 8 (2003) 379–391, https://doi.org/10.1046/j.1365-2443.
2003.00640.x.
[24] Resources, Bayl. Coll. Med. (n.d.). https://www.bcm.edu/research/labs/jeffrey-
rosen/protocols (Accessed November 6, 2019).
[25] H. Zatorski, M. Sałaga, M. Zielińska, A. Piechota-Polańczyk, K. Owczarek,
R. Kordek, U. Lewandowska, C. Chen, J. Fichna, Experimental colitis in mice is
attenuated by topical administration of chlorogenic acid, Naunyn Schmiedebergs
Arch. Pharmacol. 388 (2015) 643–651, https://doi.org/10.1007/s00210-015-
1110-9.
[26] B. Pulli, M. Ali, R. Forghani, S. Schob, K.L.C. Hsieh, G. Wojtkiewicz, J.J. Linnoila,
J.W. Chen, Measuring myeloperoxidase activity in biological samples, PLoS One 8
(2013) e67976, , https://doi.org/10.1371/journal.pone.0067976.
[27] M. Salaga, L.V. Blomster, A. Piechota-Polańczyk, M. Zielińska, D. Jacenik,
A.I. Cygankiewicz, W.M. Krajewska, J.D. Mikkelsen, J. Fichna, Encenicline, an α7
nicotinic acetylcholine receptor partial agonist, reduces immune cell infiltration in
the Colon and improves experimental colitis in mice, J. Pharmacol. Exp. Ther. 356
(2016) 157–169, https://doi.org/10.1124/jpet.115.228205.
[28] A.J. Lenaerts, C.M. Johnson, K.S. Marrieta, V. Gruppo, I.M. Orme, Significant in-
creases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs,
Int. J. Antimicrob. Agents 26 (2005) 152–158, https://doi.org/10.1016/j.
ijantimicag.2005.04.011.
[29] J.H. Park, D. Kim, B.S. Shin, Effects of propofol and isoflurane on excitatory amino
acid carrier 1 mRNA and glutathione protein levels in rat hippocampus, J. Int. Med.
Res. 46 (2018) 4705–4716, https://doi.org/10.1177/0300060518795583.
[30] T. Yang, Y. Sun, F. Zhang, Anti-oxidative aspect of inhaled anesthetic gases against
acute brain injury, Med. Gas Res. 6 (2016) 223–226, https://doi.org/10.4103/
2045-9912.196905.
[31] W. Yao, G. Luo, G. Zhu, X. Chi, A. Zhang, Z. Xia, Z. Hei, Propofol activation of the
Nrf2 pathway is associated with amelioration of acute lung injury in a rat liver
transplantation model, Oxid. Med. Cell. Longev. (2014), https://doi.org/10.1155/
2014/258567.
[32] D. Klóska, A. Kopacz, D. Cysewski, M. Aepfelbacher, J. Dulak, A. Jozkowicz,
A. Grochot-Przeczek, Nrf2 sequesters Keap1 preventing podosome disassembly: a
quintessential duet moonlights in endothelium, Antioxid. Redox Signal. (2018),
https://doi.org/10.1089/ars.2018.7505.
[33] M. Iranshahy, M. Iranshahi, S.R. Abtahi, G. Karimi, The role of nuclear factor er-
ythroid 2-related factor 2 in hepatoprotective activity of natural products: a review,
Food Chem. Toxicol. 120 (2018) 261–276, https://doi.org/10.1016/j.fct.2018.07.
024.
[34] B. Chassaing, J.D. Aitken, M. Malleshappa, M. Vijay-Kumar, Dextran sulfate sodium
A. Kopacz, et al. Biomedicine & Pharmacotherapy 128 (2020) 110317
8
(DSS)-induced colitis in mice, Curr. Protoc. Immunol. 104 (2014), https://doi.org/
10.1002/0471142735.im1525s104 Unit 15.25.
[35] Y.S. Kim, S.B. Ho, Intestinal goblet cells and mucins in health and disease: recent
insights and progress, Curr. Gastroenterol. Rep. 12 (2010) 319–330, https://doi.
org/10.1007/s11894-010-0131-2.
[36] D. Wang, R.N. Dubois, The role of COX-2 in intestinal inflammation and colorectal
cancer, Oncogene 29 (2010) 781–788, https://doi.org/10.1038/onc.2009.421.
[37] I. Stachel, C. Geismann, K. Aden, F. Deisinger, P. Rosenstiel, S. Schreiber, S. Sebens,
A. Arlt, H. Schäfer, Modulation of nuclear factor E2-related factor-2 (Nrf2) activa-
tion by the stress response gene immediate early response-3 (IER3) in colonic
epithelial cells: a novel mechanism of cellular adaption to inflammatory stress, J.
Biol. Chem. 289 (2014) 1917–1929, https://doi.org/10.1074/jbc.M113.490920.
[38] S. Mukhopadhyay, K.R. Sekhar, A.B. Hale, K.M. Channon, G. Farrugia,
M.L. Freeman, P.R. Gangula, Loss of NRF2 impairs gastric nitrergic stimulation and
function, Free Radic. Biol. Med. 51 (2011) 619–625, https://doi.org/10.1016/j.
freeradbiomed.2011.04.044.
[39] T. Rangasamy, J. Guo, W.A. Mitzner, J. Roman, A. Singh, A.D. Fryer, M. Yamamoto,
T.W. Kensler, R.M. Tuder, S.N. Georas, S. Biswal, Disruption of Nrf2 enhances
susceptibility to severe airway inflammation and asthma in mice, J. Exp. Med. 202
(2005) 47–59, https://doi.org/10.1084/jem.20050538.
[40] F. Rieder, C. Fiocchi, Intestinal fibrosis in inflammatory bowel disease - Current
knowledge and future perspectives, J. Crohns Colitis 2 (2008) 279–290, https://doi.
org/10.1016/j.crohns.2008.05.009.
[41] S. Braun, C. Hanselmann, M.G. Gassmann, U. auf dem Keller, C. Born-Berclaz,
K. Chan, Y.W. Kan, S. Werner, Nrf2 transcription factor, a novel target of kerati-
nocyte growth factor action which regulates gene expression and inflammation in
the healing skin wound, Mol. Cell. Biol. 22 (2002) 5492–5505.
[42] L.E. Randle, C.E.P. Goldring, C.A. Benson, P.N. Metcalfe, N.R. Kitteringham,
B.K. Park, D.P. Williams, Investigation of the effect of a panel of model hepatotoxins
on the Nrf2-Keap1 defence response pathway in CD-1 mice, Toxicology. 243 (2008)
249–260, https://doi.org/10.1016/j.tox.2007.10.011.
[43] I.Y. Adamson, D.H. Bowden, The pathogenesis of bleomycin-induced pulmonary
fibrosis in mice, Am. J. Pathol. 77 (1974) 185–197.
[44] H.-M. Ni, N. Boggess, M.R. McGill, M. Lebofsky, P. Borude, U. Apte, H. Jaeschke,
W.-X. Ding, Liver-specific loss of Atg5 causes persistent activation of Nrf2 and
protects against acetaminophen-induced liver injury, Toxicol. Sci. Off. J. Soc.
Toxicol. 127 (2012) 438–450, https://doi.org/10.1093/toxsci/kfs133.
[45] R. Ashoor, R. Yafawi, B. Jessen, S. Lu, The contribution of lysosomotropism to
autophagy perturbation, PLoS One 8 (2013) e82481, https://doi.org/10.1371/
journal.pone.0082481.
A. Kopacz, et al. Biomedicine & Pharmacotherapy 128 (2020) 110317
9
